Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice.

Alexander JM, Bab I, Fish S, Müller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Sept 2001Cited by 127 (Europe PMC)

PMID11547836DOI10.1359/jbmr.2001.16.9.1665PepBankPUB-11547836

Source link PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, PTH recovered approximately 35% of trabecular bone loss versus vehicle.
In plain wordsIn mice, PTH partly restored trabecular bone volume compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone volume recovery
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
PTH induced a approximately 35% recovery of this loss and a approximately 40% reversal of the associated decreases in trabecular number (Tb.N) and connectivity.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
Report a problemFND-1154783601
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, PTH reversed approximately 40% of the decrease in trabecular number versus vehicle.
In plain wordsIn mice, PTH partly restored trabecular number compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular number
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
PTH induced a approximately 35% recovery of this loss and a approximately 40% reversal of the associated decreases in trabecular number (Tb.N) and connectivity.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
Report a problemFND-1154783602
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, PTH reversed approximately 40% of the decrease in trabecular connectivity versus vehicle.
In plain wordsIn mice, PTH partly restored trabecular connectivity compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular connectivity
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
PTH induced a approximately 35% recovery of this loss and a approximately 40% reversal of the associated decreases in trabecular number (Tb.N) and connectivity.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
Report a problemFND-1154783603
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, PTH shifted trabecular surfaces from single to double calcein labeling versus vehicle.
In plain wordsIn mice, PTH increased double-labeled trabecular surfaces compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCalcein-labeled surfaces
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
PTH also caused a shift from single to double calcein-labeled trabecular surfaces, a significant enhancement in the mineralizing perimeter and a respective 2- and 3-fold stimulation of the mineral appositional rate (MAR) and bone formation rate (BFR).
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
Report a problemFND-1154783604
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, PTH significantly increased the mineralizing perimeter versus vehicle.
In plain wordsIn mice, PTH increased the mineralizing perimeter compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMineralizing perimeter
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
PTH also caused a shift from single to double calcein-labeled trabecular surfaces, a significant enhancement in the mineralizing perimeter and a respective 2- and 3-fold stimulation of the mineral appositional rate (MAR) and bone formation rate (BFR).
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
Report a problemFND-1154783605
06AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, PTH stimulated trabecular mineral appositional rate versus vehicle.
In plain wordsIn mice, PTH increased trabecular mineral apposition compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular mineral appositional rate
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Measurements
MAR stimulation
2 fold
PTH
Source sentences
Summary
PTH also caused a shift from single to double calcein-labeled trabecular surfaces, a significant enhancement in the mineralizing perimeter and a respective 2- and 3-fold stimulation of the mineral appositional rate (MAR) and bone formation rate (BFR).
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
Report a problemFND-1154783606
07AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, PTH stimulated trabecular bone formation rate versus vehicle.
In plain wordsIn mice, PTH increased trabecular bone formation compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone formation rate
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Measurements
BFR stimulation
3 fold
PTH
Source sentences
Summary
PTH also caused a shift from single to double calcein-labeled trabecular surfaces, a significant enhancement in the mineralizing perimeter and a respective 2- and 3-fold stimulation of the mineral appositional rate (MAR) and bone formation rate (BFR).
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
Report a problemFND-1154783607
08AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, PTH increased diaphyseal endosteal cortical mineral appositional rate versus vehicle.
In plain wordsIn mice, PTH increased endosteal cortical mineral apposition compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndosteal cortical mineral appositional rate
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Diaphyseal endosteal cortical MAR and thickness also were increased with a high correlation between these parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
Report a problemFND-1154783608
09AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized mice, PTH increased diaphyseal cortical thickness versus vehicle.
In plain wordsIn mice, PTH increased cortical thickness compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical thickness
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Diaphyseal endosteal cortical MAR and thickness also were increased with a high correlation between these parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
Report a problemFND-1154783609

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

10AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In ovariectomized mice, diaphyseal endosteal cortical mineral appositional rate correlated highly with cortical thickness.
In plain wordsIn mice, cortical mineral apposition correlated with cortical thickness.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableCortical apposition-thickness correlation
Study
mousen: not reported in source
Ovariectomized Swiss-Webster mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Diaphyseal endosteal cortical MAR and thickness also were increased with a high correlation between these parameters.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1154783610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.